iShares Genomics Immunology and Healthcare ETF Stock Forecast, Price & News

Wall Street analysts have given iShares Genomics Immunology and Healthcare ETF a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but iShares Genomics Immunology and Healthcare ETF wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

iShares Genomics Immunology and Healthcare ETF's stock was trading at $26.77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IDNA shares have increased by 86.0% and is now trading at $49.79.
View which stocks have been most impacted by COVID-19.

iShares Genomics Immunology and Healthcare ETF pays an annual dividend of $0.09 per share and currently has a dividend yield of 0.18%.
View iShares Genomics Immunology and Healthcare ETF's dividend history.

Based on aggregate information from My MarketBeat watchlists, some companies that other iShares Genomics Immunology and Healthcare ETF investors own include Pfizer (PFE), Gilead Sciences (GILD), Intel (INTC), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Novavax (NVAX), Canadian Natural Resources (CNQ), QUALCOMM (QCOM), SPDR S&P Biotech ETF (XBI) and Bristol-Myers Squibb (BMY).

iShares Genomics Immunology and Healthcare ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "IDNA."

iShares Genomics Immunology and Healthcare ETF's stock is owned by many different institutional and retail investors. Top institutional investors include Wealthcare Advisory Partners LLC (1.44%), Baird Financial Group Inc. (0.71%), Cambridge Investment Research Advisors Inc. (0.38%), Outlook Wealth Advisors LLC (0.26%), Flow Traders U.S. LLC (0.20%) and Sigma Planning Corp (0.10%).

IDNA stock was sold by a variety of institutional investors in the last quarter, including James Investment Research Inc..

IDNA stock was bought by a variety of institutional investors in the last quarter, including Baird Financial Group Inc., Wealthcare Advisory Partners LLC, Flow Traders U.S. LLC, Wealthcare Capital Management LLC, Cambridge Investment Research Advisors Inc., Outlook Wealth Advisors LLC, and Sigma Planning Corp.

Shares of IDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IDNA stock can currently be purchased for approximately $49.79.

iShares Genomics Immunology and Healthcare ETF has a market capitalization of $308.70 million.